News

Multiple Myeloma Research Consortium Welcomes Karmanos Cancer Institute as Member

View Comments
Karmanos Cancer Institute. (File)

Karmanos Cancer Institute. (File)

CBS Detroit (con't)

Affordable Care Act Updates: CBSDetroit.com/ACA

Health News & Information: CBSDetroit.com/Health

NORWALK, Conn. — The Multiple Myeloma Research Consortium today announced that it has expanded its clinical research network to include the Barbara Ann Karmanos Cancer Institute in Detroit.

Following a rigorous evaluation, this NCI-designated comprehensive cancer center joins the existing MMRC member institutions in promoting and facilitating collaborative research and accelerating drug development in multiple myeloma, an incurable blood cancer.

“We are proud to join such a highly respected model for accelerating the development of new treatment options for multiple myeloma patients,” said Jeffrey Zonder, M.D., associate professor of Medicine and Oncology, Karmanos Cancer Institute and Wayne State University School of Medicine. “We are very much looking forward to collaborating with the MMRC, its elite member institutions, and its partners in the biotech and pharmaceutical industries to bring patients the next generation of multiple myeloma treatments.”

As an MMRC member institution, Karmanos will participate in all clinical research activities of the consortium, including the conduction of Phase I and II clinical trials of promising myeloma treatments. In this role, Karmanos will also contribute multiple myeloma patient tissue samples to the MMRC Tissue Bank, a cutting-edge resource that bridges laboratory and clinical research.

Said Beverly Harrison, vice president of clinical development at the consortium: “Like all MMRC Member Institutions, Karmanos was selected to join this exclusive network based on its outstanding reputation for clinical excellence, its demonstrated commitment to rigorous research, and its true spirit of collaboration and team-science. We have no doubt that Karmanos will prove to be an invaluable asset in our efforts to rapidly shepherd the next generation of treatments through the MMRC.”

The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 16 member institutions. More at www.themmrc.org.

The Karmanos Cancer Institute is one of 40 National Cancer Institute-designated comprehensive cancer centers in the United States.

View Comments
blog comments powered by Disqus
Follow

Get every new post delivered to your Inbox.

Join 2,357 other followers